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Low-dose opioids and constipation
Opioid-induced constipation: 
avoiding the perils and pitfalls
Alain Borgeat, Head of the Department of Anaesthesiology,  
Orthopaedic University Hospital Balgrist, Switzerland
Chronic pain is a serious issue in many 
Western countries. In Europe its incidence 
ranges from 30 per cent in Norway to 11 
per cent in Spain. Long-term treatment 
with opioids has usually been prescribed 
for chronic pain associated with cancer, 
but recent evidence has shown the benefits 
of this class of drugs in the treatment of 
chronic neuropathic pain of diverse aeti-
ologies. Considering the new indications 
of long-term opioid therapy, it is nowadays 
difficult to imagine the practice of chronic 
pain therapy without their use. 
Although µ-opioid agonists provide 
effective analgesia they also produce a 
large number of other undesirable effects. 
Among them gastrointestinal dysfunction 
(nausea, vomiting and constipation) is of 
particular concern since its occurrence 
increases patients’ distress and enhances 
the level of pain. Tolerance commonly 
develops to most of the effects of opioids 
on the gastrointestinal tract, but constipa-
tion often persists. Constipation is consid-
ered by many patients to be the most 
debilitating adverse effect associated with 
opioid therapy. 
Physiopathology of opioid-induced 
constipation
The interaction between opioids and the 
GI tract is complex and is mainly mediated 
by the µ-opioid receptor, although ∂- and 
k-receptors are also implicated to a certain 
extent. The GI tract is innervated by the 
enteric nervous system which comprises 
the myenteric plexus, located between cir-
cular and longitudinal smooth muscle lay-
ers of the bowel and the submucosal plexus, 
located in the submucosa. Enteric neurons 
are responsible for the synthesis and 
release of opioid peptides (encephalins) 
and their transmitters. These mediators 
participate in co-ordination of the contrac-
tile process under physiological conditions 
and can decrease intestinal motility in cases 
of inflammation, trauma or stress. 
The binding of opioids to the µ-receptor 
leads to the inhibition of excitatory and 
inhibitory neurotransmitter release. The 
consequences are interruption of the co-
ordinated rhythmic contractions required 
for intestinal motility and decrease of 
propulsive peristaltic activity. Some areas 
of the GI tract show increased tone and 
spasms, thereby delaying gastric empty-
ing and further slowing intestinal trans-
port. Opioid binding also inhibits 
secretion while increasing absorption of 
fluids. The net result is the formation of 
dry, hard stools that are difficult to pass. 
Opioid tolerance and constipation
With repeated exposure to morphine, tol-
erance does not develop to constipation 
as it does to other effects such as anal-
gesia, nausea and vomiting or pruritus. It 
has been suggested that upregulation of 
the drug efflux protein P-glycoprotein is 
required for tolerance development. 
Studies have demonstrated that morphine 
induces P-glycoprotein upregulation in 
the brain, but it does not upregulate 
 intestinal P-glycoprotein.1
Handling opioid-induced constipation 
Constipation management is an important 
issue as patients suffering from opioid-
induced constipation have decreased lev-
els of activity, miss more work and have 
decreased health-related quality of life 
scores. Apart from instituting a prophylac-
tic laxative regimen, the physician does 
not have many options for resolving this 
A hazardous journey: 
tackling opioid-
induced 
constipation without 
losing effective pain 
control can be a 
difficult undertaking
problem. On the one hand reducing the 
opioid dosage may increase levels of pain, 
and on the other hand if constipation 
becomes more severe the patient may 
decide to stop the opioid treatment. Like 
Ulysses in Greek mythology, the physician 
must decide how to navigate the narrow 
strait between Scylla the six-headed mon-
ster and Charybdis the whirlpool. Ulysses 
was smart enough to successfully sail 
between these two dangers, although he 
lost a few crew members along the way. 
Decreasing the morphine dosage is not 
the best way to move forward as the dose 
of opioids that induces constipation is 
much smaller than that required for anal-
gesia. Opioid-induced constipation is 
seen even with a single administration of 
morphine. Even a low dose of morphine 
(0.05mg/kg) was shown to increase oral to 
caecum transit time by 40 per cent.2 
Reducing the severity of constipation by 
lowering the morphine dosage requires a 
dramatic reduction of opioid which will 
probably result in an increased pain 
severity for the patient, thereby increas-
ing the patient’s distress. Conditions for a 
vicious circle are set up. The only viable 
reason to decrease opioid dosage in this 
setting would be the suspicion of opioid-
induced hyperalgesia. 
To escape from this dilemma some steps 
need to be undertaken. The first is not to 
give in to temptation to reduce the mor-
phine dosage. Control of the pain is a high 
priority and it should remain efficient. 
Moreover, we know that this measure is 
unlikely to reduce the severity of the con-
stipation. The second step is to plan a pro-
phylactic laxative regimen, which should 
be started at the time opioid therapy 
begins.
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